22 June 2023  
EMA/279923/2023 
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Trodelvy 
sacituzumab govitecan 
On 22 June 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Trodelvy. The marketing authorisation holder for this medicinal product is Gilead Sciences Ireland UC. 
The CHMP adopted a new indication for the treatment of hormone receptor (HR)-positive, HER2-negative 
breast cancer. 
For information, the full indications for Trodelvy will be as follows2: 
Trodelvy as monotherapy is indicated for the treatment of adult patients with unresectable or 
metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic 
therapies, including at least one of them for advanced disease (see section 5.1). 
Trodelvy as monotherapy is indicated for the treatment of adult patients with 
unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast 
cancer who have received endocrine-based therapy, and at least two additional 
systemic therapies in the advanced setting (see section 5.1). 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2023. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
 
